Hexatronic Group (OTC:HTROF) Stock, Quote.Headers.trade-ideas

Hexatronic Group AB is a technology group, specializing in fiber communications products. The company supplies fiber optic products and solutions; and a complete range of passive infrastructure for telecom companies.

HEXATRONIC GROUP AB by HEXATRONIC GROUP AB

Hexatronic Group AB

UBS analyst Trung Huynh initiates coverage on Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) with a Buy rating and announces Price Target of $10.

News

Price Target

Initiation

Analyst Ratings

CABA

UBS Initiates Coverage On Cabaletta Bio with Buy Rating, Announces Price Target of $10

Reqorsa&#xAE; Gene Therapy Overcomes Acquired Resistance to Lumakras&#xAE; in Lung Cancer
REQORSA Demonstrated Potent Tumor Suppressive Activity in Mesothelioma
REQORSA Induces Apoptosis in Glioblastoma
AUSTIN, Texas, Oct. 10, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4275148-1&amp;h=2033031084&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a> ("Genprex" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnpx#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024 in Barcelona, Spain. The collaborators will present posters on positive preclinical data from studies of its lead drug candidate, Reqorsa&#xAE; Gene Therapy (quaratusugene ozeplasmid), for the treatment of Ras inhibitor resistant lung cancer, mesothelioma and glioblastoma.

Biotech

Penny Stocks

General

GNPX

Genprex Collaborators To Present Preclinical Data On The Use Of Reqorsa Gene Therapy At The 2024 EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics

MainStreet Bancshares Issues Guidance for Third Quarter 2024 Earnings
FAIRFAX, Va., October 10, 2024 &ndash; MainStreet Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSB#NASDAQ">MNSB</a>, MNSBP)))), the holding company for MainStreet Bank, today issued guidance for its upcoming third quarter earnings. The Company estimates a loss of four cents per common share for the third quarter.
During the third quarter, the Company charged-off $1.9 million to successfully offload $21.8 million in nonperforming loans. The loans originated between March 2020 and April 2021, and bore the full brunt of pandemic-related construction delays, higher costs, supply chain delays and rapidly increasing interest rates.
In addition, the Company reversed $983,000 of accrued interest income, and paid $593,519 in nonrecurring liquidation expenses. The Company made a provision of $1 million to support loan growth and ensure the Allowance for Credit Losses is directionally consistent.

Guidance

MNSB

Mainstreet Bancshares Estimates Q3 EPS Of $(0.04) Per Share

Indivior PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) shares are trading lower after the company reported preliminary third-quarter revenue results&nbsp;and cut its FY24 net <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41268380/indivior-provides-preliminary-q3-2024-results-updates-fy-2024-guidance-group-continues-to-expect-s" rel="noreferrer noopener">revenue guidance below estimates</a>.
The company expects third-quarter net revenue of&nbsp;$302 million&nbsp;&#8211;&nbsp;$309 million versus the consensus of $289.37 million.
Also, Indivior trimmed its FY24 net revenue&nbsp;outlook&nbsp;to $1.125 billion &#8211; $1.165 billion (consensus&nbsp;$1.185 billion) from&nbsp;$1.15 billion &#8211; $1.215 billion.
In particular, the company now expects lower-than-anticipated net revenue for SUBLOCADE, with projected net revenue of $187 million &#8211; $192 million in the third quarter and $725 million &#8211; $745 million (versus $765 million to $805 million expected earlier) for FY24.
Mark Crossley, CEO of Indivior, stated, &#8220;We are seeing faster than expected initial adoption of the competitive product to SUBLOCADE. This dynamic, together with greater variability in the timing of funding among Criminal Justice System customers, as well as incremental trade stocking pressure, has resulted in net revenue below our expectations set out in July. We are reducing our FY 2024&nbsp;guidance&nbsp;to reflect these impacts.&#8221;
Also, looking to the year ahead, the company expects pressure on SUBLOCADE volume growth from continued initial competitor adoption as the&nbsp;U.S. market adjusts to two long-acting injectable products.
Indivior maintained its expectation for peak net revenue from SUBLOCADE to exceed $1.5 billion but no longer anticipates a run rate of $1 billion by the end of 2025.
Crossle added, &#8220;We remain firm in our conviction that SUBLOCADE has a differentiated and optimal profile for opioid use disorder (OUD) patients, including our belief that it will best meet the increasing challenges that synthetic opioids are presenting to OUD patients and treatment providers.&#8221;
&#8221;Additionally, we expect SUBLOCADE&#8217;s profile to be further enhanced with important label updates in&nbsp;February 2025&nbsp;that, if approved by the FDA, are expected to improve both the patient and healthcare provider experience.&#8221;
Apart from this, the company reiterated outlook for an adjusted gross margin in low to mid 80% range and lowered adjusted operating profit guidance to $260 million &#8211; $280 million (from<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> $285 million &#8211; $320 million) for 2024</a>.
Price Action: INDV shares are down 16.6% at $7.87 premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40722274/french-biotech-candidate-for-cannabis-use-disorder-fails-phase-2b-clinical-trial-indivior-will-n" target="_blank" rel="noreferrer noopener">French Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior Will Not Exercise Option</a></li>
</ul>

Equities

Small Cap

Movers

INDV

Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details

<a href="https://www.mastercard.com/news/europe/en/newsroom/press-releases/en/2024/vodafone-sumitomo-corporation-and-mastercard-team-up-to-advance-the-economy-of-things/#" title="https://www.mastercard.com/news/europe/en/newsroom/press-releases/en/2024/vodafone-sumitomo-corporation-and-mastercard-team-up-to-advance-the-economy-of-things/#">https://www.mastercard.com/news/europe/en/newsroom/press-releases/en/2024/vodafone-sumitomo-corporation-and-mastercard-team-up-to-advance-the-economy-of-things/#</a>

'Vodafone, Sumitomo Corporation, and Mastercard team up to advance the economy of things' - Mastercard

Truist Securities analyst Youssef Squali maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $570 to $650.

Truist Securities Maintains Buy on Meta Platforms, Raises Price Target to $650

By <a href="https://roboforex.com/beginners/analytics/forex-forecast/?utm_source=benzinga.com&amp;utm_medium=pr&amp;utm_campaign=rf_en_external_article_10102024&amp;utm_content=analysis&amp;utm_term=forecast" style="color:#0563c1; text-decoration:underline">RoboForex Analytical Department</a>
The AUD/USD pair has halted its nearly continuous seven-day decline, stabilising around 0.6730 on Thursday. This level marks the monthly low for the Australian dollar, which has faced significant pressures lately due to a strengthening US dollar and uncertainties in China, Australia&#39;s largest trading partner.
<h3>Market Influences And Economic Indicators</h3>
The recent US jobs report and the Federal Reserve&#39;s latest meeting minutes have led investors to reassess their expectations for future US rate cuts, affecting the currency pair. Additionally, no new stimulus measures have been announced in China, impacting sentiment, given that earlier stimulative actions are still not fully reflected in the economic performance.
In Australia, inflation expectations have decreased to a three-year low of 4% in October, providing a somewhat positive signal. However, the minutes from the Reserve Bank of Australia&#39;s (RBA) latest meeting revealed discussions around both potential rate cuts and hikes, reflecting ongoing uncertainty about the economic outlook. The RBA concluded that the current interest rate appropriately balances the risks associated with inflation and labour market conditions.
<h3>AUD/USD Technical Analysis</h3>
<a href="https://www.benzinga.com/files/u117641/audusdh4_20.png"><img alt="" src="https://www.benzinga.com/files/u117641/audusdh4_20.png" style="height:277px; width:624px" /></a>
The AUD/USD pair recently completed a downward wave to 0.6707 and is now forming a consolidation range above this level. If the pair breaks downwards, it could target a further decline to 0.6682. Conversely, an upward break might lead to a corrective move towards 0.6796. After this correction, the downward trend could continue towards 0.6655. The MACD indicator supports a bearish outlook, with its signal line positioned below zero and trending downwards.
<a href="https://www.benzinga.com/files/u117641/audusdh1_18.png"><img alt="" src="https://www.benzinga.com/files/u117641/audusdh1_18.png" style="height:277px; width:624px" /></a>
On the hourly chart, the pair is consolidating around 0.6734. An upward breakout could lead to a rise towards 0.6815. Following this, a new downward phase could begin, potentially reaching 0.6710. If this level is breached, the decline could extend towards 0.6682. The Stochastic oscillator, with its signal line below 80 and poised to move downwards, aligns with this potential downward trajectory.
Conclusion
Investors and traders should closely monitor further developments from both the Federal Reserve and the RBA, as well as any new economic data from China, which could significantly influence the direction of the AUD/USD pair. The complex interplay of US monetary policy expectations, Chinese economic actions, and domestic Australian economic indicators will likely continue to drive volatility in the currency pair.
Disclaimer
Any forecasts contained herein are based on the author&#39;s particular opinion. This analysis may not be treated as trading advice. RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Forex

Markets

Trading Ideas

AUD/USD Stabilises Near Monthly Low Amid Mixed Signals

Truist Securities analyst Srikripa Devarakonda maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Buy and raises the price target from $1000 to $1033.

Truist Securities Maintains Buy on Eli Lilly, Raises Price Target to $1033

As of Oct. 10, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Travere Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>)</h3>
<ul>
<li>On Sept. 26, Travere Therapeutics announced a voluntary pause of enrollment in its Phase 3 HARMONY study of Pegtibatinase. The company's stock gained around 27% over the past five days and has a <a href="https://www.benzinga.com/quote/TVTX">52-week high of $17.77</a>.</li>
<li>RSI Value: 86.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TVTX Price Action: Shares of Travere Therapeutics gained 15.7% to close at $17.59 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Masimo Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>)</h3>
<ul>
<li>Michelle Brennan, a current member of Masimo's Board, has taken on the role of interim Chief Executive Officer, after Joe Kiani announced his resignation as CEO. In a regulatory filing, the company disclosed that, on September 19, Kiani filed a claim in California state court relating to his employment agreement, as amended, seeking declaratory relief that he had validly terminated his employment for "Good Reason." Masimo said its Board is evaluating Kiani's notice as well as his lawsuit against the company. The company's stock gained around 25% over the past month and <a href="https://www.benzinga.com/quote/MASI">has a 52-week high</a> of $153.93.</li>
<li>RSI Value: 75.44</li>
<li>MASI Price Action: Shares of Masimo rose 2.5% to close at $143.49 on Wednesday.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41266054/s-p-settles-at-record-high-as-apple-amazon-shares-surge-investor-optimism-improves-ahead-of-inflati">S&amp;P Settles At Record High As Apple, Amazon Shares Surge: Investor Optimism Improves Ahead Of Inflation Data</a></li>
</ul>

Short Ideas

Pre-Market Outlook

MASI

TVTX

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

Scotiabank analyst Paul Cheng downgrades BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) from Sector Outperform to Sector Perform and lowers the price target from $42 to $36.

Downgrades

Scotiabank Downgrades BP to Sector Perform, Lowers Price Target to $36

Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) with a Speculative Buy and maintains $5 price target.

Reiteration

GDTC

Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Ladenburg Thalmann analyst Mickey Schlelen downgrades Saratoga Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>) from Buy to Neutral.

Ladenburg Thalmann Downgrades Saratoga Investment to Neutral

CDTA buses now equipped with Gauzy's innovative Smart-Vision&#xAE; camera monitor system (CMS) as part of a multi-year phase-in program to improve road safety &nbsp;
Company estimates that its cumulative sales for its commercial vehicle CMS/ADAS will surpass $100,000,000 by the end of 2025
Broad global interest in ADAS expected to generate new growth opportunities for Gauzy's Safety Tech division
NEW YORK and TEL AVIV, Israel, Oct. 10, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YbLzQVyqbcBn2yZh1Yr9GgOgB0foJ5x2_ZVbjLFAbKyiusM--ppJqHtdip1G2vRfpprSF764tF4UiGB8XWpIrw==">Gauzy Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAUZ#NASDAQ">GAUZ</a>) ("Gauzy" or the "Company"), a global leader in light and vision control technology, is pleased to announce that its advanced driver assistance system (ADAS) has fully replaced traditional side mirrors on the Capital District Transportation Authority (CDTA) of New York's public buses. Gauzy's Smart-Vision&#xAE; camera monitor system (CMS) was unveiled on CDTA's buses at a special ceremony on October 3, 2024, signifying the next phase of CDTA's multi-year phase-in program designed to improve road safety. This milestone demonstrates CDTA's confidence in the technology's ability to optimize visibility by reducing blind spots.
The Smart Vision&#xAE; CMS was installed on the CDTA buses by Luminator Technology Group, who serves as Gauzy's exclusive distribution partner for transit agencies in North America and markets the system as Luminator Video Mirror in the region. Gauzy has been quickly capturing market share across North America, Europe, Asia and Australia as transportation officials have demonstrated heightened interest in ADAS and expediting the necessary regulatory approvals required to install it in public buses and coaches. As a result, Gauzy estimates that its cumulative sales for its commercial vehicle CMS/ADAS will surpass $100 million by the end of 2025.

Contracts

GAUZ

Gauzy's Advanced Driver Assistance System Fully Replaces Traditional Side Mirrors On Capital District Transportation Authority Of New York's Public Buses; Company Estimates That Its Cumulative Sales For Its Commercial Vehicle CMS/ADAS Will Surpass $100M By The End Of 2025

Truist Securities analyst Srikripa Devarakonda maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Buy and raises the price target from $210 to $215.

ABBV

Truist Securities Maintains Buy on AbbVie, Raises Price Target to $215

<a href="https://www.federalreserve.gov/newsevents/speech/cook20241010a.htm" title="https://www.federalreserve.gov/newsevents/speech/cook20241010a.htm">https://www.federalreserve.gov/newsevents/speech/cook20241010a.htm</a>

Federal Reserve

Fed's Cook Does Not Comment On Economic Or Monetary Policy Outlook In Prepared Remarks At Event In South Carolina

Seaport Global analyst Daniel Mckenzie downgrades Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) from Buy to Neutral.

AZUL

Seaport Global Downgrades Azul to Neutral

In a <a href="https://www.youtube.com/live/AD5Y9IMENys?si=ZhokQrUut17hwCrh&amp;t=2686">recent episode</a> of The Ramsey Show, <a href="https://www.benzinga.com/personal-finance/24/10/41213012/dave-ramseys-bold-plan-to-fight-inflation-could-his-radical-approach-help-you-keep-more-cash-in-">Dave Ramsey</a> responded to a caller, Daniel from Houston, who asked if his aggressive investment plan was too extreme.&nbsp;
Daniel and his wife, both recent college graduates, earn a $200,000 household income with a take-home pay of $145,000 after deductions. They live in an apartment and have zero debt, a six-month emergency fund, and a goal of having Daniel's wife become a stay-at-home mother. Daniel asked Dave Ramsey whether they were going overboard by investing 60% of their take-home pay while <a href="https://www.benzinga.com/personal-finance/24/10/41196513/more-expenses-more-taxes-more-everything-suze-orman-on-the-risks-of-upgrading-to-a-swanky-apartm">living in an apartment</a>.
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
<li>Beating the market through ethical real estate investing' — t<a href="https://www.benzinga.com/money/invest-with-roots">his platform aims to give tenants equity in the homes they live in while scoring 17.17% average annual returns for investors – here&#8217;s how to join with just $100</a></li>
</ul>
Ramsey's advice was rooted in the long-term wealth-building habits he's studied over the years. While Daniel's diligence in budgeting and saving is admirable, Ramsey pointed out that the plan has a critical flaw: housing. According to Ramsey, living in an apartment means subjecting yourself to increasing rent year after year, which could erode the benefits of investing so heavily.
See Also: A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a>
Ramsey explained that very few of the <a href="https://www.benzinga.com/personal-finance/24/10/41146426/can-you-guess-the-top-5-careers-of-millionaires-according-to-dave-ramsey-spoiler-alert-theyre-no">millionaires</a> he's studied followed a path that involved renting long-term while investing aggressively. Instead, most bought homes and focused on paying them off. By owning a home, Daniel and his wife could stabilize their largest budget item – housing – and eventually eliminate it. "Your largest item is out of your control, and it's going up every year," Ramsey warned, highlighting the need to move away from renting as soon as possible.
The logic behind Ramsey's advice is simple: homeownership locks in a fixed cost for housing, whereas rent will continually rise. Over 15 years, paying off a house can lead to a significant net worth boost, Ramsey explained, with much of that wealth tied to both the home and the couple's retirement accounts.
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
<a href="https://www.benzinga.com/personal-finance/24/10/41165091/37-year-old-millionaire-confesses-hes-miserable-and-lacks-purpose-ramsey-host-tells-him-we-dont-">Ken Coleman</a>, who co-hosted the show with Ramsey, added another perspective. He emphasized that while Daniel might be comfortable living frugally in an apartment, his wife might not feel the same way in the long run.&nbsp;
"She's going to want a house," Coleman said, urging Daniel to think ahead. Ramsey echoed this, pointing out that while Daniel's intense savings plan was admirable, it needed to be aligned with a broader, more balanced approach to wealth-building, including homeownership.
Trending: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
Ramsey's overall advice to Daniel was to scale back the extreme savings strategy. Instead of investing 60% of their income, Ramsey suggested sticking to a 15% retirement savings goal while they work toward owning a home. He also advised the couple to stop funding their HSA (health savings account) for now and focus on building a down payment for a house. Ramsey noted that Daniel would likely see substantial home appreciation over the years, contributing to long-term wealth.
Other experts also state that buying a home is a smart investment strategy – not just for those looking to amp up a real estate portfolio but for the average homeowner.&nbsp;
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a>
"It's hard to argue against the long-term financial value of homeownership," Martin Orefice, CEO of Rent To Own Labs, told Bankrate. "Real estate usually appreciates over time in the long run. While there are economic boom and bust cycles that can make real estate a losing investment in the short run, over 10 years or longer, buyers will usually come out ahead."
Investing aggressively can be a good thing, but many financial experts say owning a home is a good step to take to build wealth. Renting may offer short-term flexibility, but the long-term financial advantage lies in stabilizing your housing costs by buying a home and eventually paying it off. By following a balanced plan of moderate investing and saving for a home, Daniel and his wife will be well-positioned for financial success.
If you're unsure about your financial plan, consider speaking with a <a href="https://www.benzinga.com/money/best-online-financial-advisors">financial advisor</a> to ensure your strategy is aligned with your long-term goals.
Read Next:
<ul>
<li>Can you guess which type of investments Morgan Stanley says will reach $2.7 trillion by 2027?<a href="https://www.benzinga.com/money/percent"> It even offers up to 20% APY potential to accredited investors up to $300 back in bonus for new users.</a></li>
<li>Rory McIlroy&#8217;s mansion in Florida is worth $22 million today, doubling from 2017 —<a href="https://benzinga.com/money/rory-mcilroys-florida-mansion-doubled-in-value"> here&#8217;s how to get started investing in real estate with just $100</a></li>
</ul>

Personal Finance

Living in an Apartment And Investing 60% – Is It A Smart Plan? Dave Ramsey's Response To Houston Grads

Toronto Dominion Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TD#NYSE">TD</a>) is reportedly preparing to settle charges related to its alleged failure to monitor money laundering by drug cartels, the Wall Street Journal said in an <a target="_blank" href="https://www.wsj.com/finance/regulation/td-bank-faces-3-billion-in-penalties-and-growth-restrictions-in-u-s-settlement-3e09a705" rel="noreferrer noopener">exclusive report</a>.
The Canadian bank is expected to pay approximately $3 billion in penalties and face restrictions on its U.S. growth.
Under the expected agreement, TD Bank&#8217;s U.S. entity will likely plead guilty to criminal charges stemming from a DOJ investigation.
This settlement could be announced as early as today and involves multiple agencies, including the U.S. Department of Justice (DOJ), the Office of the Comptroller of the Currency (OCC), the Financial Crimes Enforcement Network (FinCEN), and the Federal Reserve.
According to the WSJ report, the DOJ and FinCEN are set to impose independent monitors to oversee the bank&#8217;s compliance with anti-money-laundering regulations. The FinCEN monitor will reportedly remain in place for four years.
The penalties will be divided between the DOJ and FinCEN, with the DOJ receiving $1.8 billion and FinCEN receiving $1.3 billion.
The bank has acknowledged the severity of its AML deficiencies, with outgoing CEO Bharat Masrani stating that resolving these <a target="_blank" href="https://www.benzinga.com/news/24/09/40941233/whats-going-on-with-toronto-dominion-bank-today" rel="noreferrer noopener">issues is a top priority</a>.
Masrani, who announced his decision to step down as CEO later this year, has been at the forefront of TD&#8217;s efforts to address regulatory concerns. In August, the bank set aside an additional $2.6 billion in anticipation of the settlement costs.
TD Bank is due to host a <a target="_blank" href="https://www.benzinga.com//node/41267914" rel="noreferrer noopener">conference call today</a>.
The case has had significant consequences for TD, including halting its $13.4 billion acquisition of First Horizon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) due to U.S. regulators&#8217; concerns over the bank&#8217;s anti-money-laundering capabilities.
The companies terminated the merger agreement in May 2023, which was announced initially in February 2022. TD paid First Horizon a $200 million cash payment and the $25 million fee reimbursement due to First Horizon under the merger agreement.&nbsp;
The OCC will impose an asset cap on TD&#8217;s U.S. business, similar to the restrictions imposed on Wells Fargo Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) in 2018 after its fake account scandal, the report highlighted.
The investigation into TD Bank intensified when federal authorities discovered that a Chinese criminal group had laundered millions of dollars from fentanyl sales through TD&#8217;s branches in New York and New Jersey, bribing bank employees in the process.
This incident, among others, has forced TD to overhaul its internal controls and strengthen its AML and investigations teams with new hires.
Price Action: At last check on Thursday, TD stock was down 4.74% at $60.50 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41270285/amazon-pharmacy-to-double-service-areas-offer-same-day-medication-delivery" target="_blank" rel="noreferrer noopener">Amazon Pharmacy to Double Service Areas, Offer Same-Day Medication Delivery</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Government

Large Cap

Legal

Media

TD Bank To Face $3B Penalty, Growth Limits In US Settlement Over Anti-Money Laundering Failures

Benchmark analyst Mark Zgutowicz reiterates Criteo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>) with a Buy and maintains $56 price target.

CRTO

Benchmark Reiterates Buy on Criteo, Maintains $56 Price Target

JP Morgan analyst Stephen Tusa downgrades Hubbell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) from Overweight to Neutral and raises the price target from $385 to $454.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Hexatronic Group

Hexatronic Group (HTROF) Forecast

Hexatronic Group (OTC:HTROF) Stock, Quote.Headers.trade-ideas